J&J Vision Launches Next-Generation iDesign Refractive Studio for LASIK

September 7, 2018: By Joan McKenna

Johnson & Johnson Vision announced Sept. 6 that it has launched the next-generation iDesign Refractive Studio.

The LASIK platform gained US approval in June 2018.

The iDesign Refractive Studio is indicated for myopia, hyperopia, mixed astigmatism, and monovision treatment of presbyopic patients with low to moderate myopia with and without astigmatism.

J&J Vision, the Santa Ana, California-based ophthalmic surgical division of Johnson & Johnson, said the platform is the only system to use topography-integrated, wavefront-guided technology.

The company said the procedure begins with wavefront analysis to measure how light travels inside the eye, detailing the imperfections in a patient’s vision. Then, the surgeon uses corneal topography to scan the outside surface of the eye, measuring and analyzing tiny variations in curvature and elevation. The combination of the two measurements produces a custom LASIK procedure for each eye.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales